Curanex Pharmaceuticals宣布首次公开募股定价

2025-08-26 19:39

Curanex Pharmaceuticals (NASDAQ:CURX) announced on Tuesday the pricing of its initial public offering of 3.75 million shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses.
The company’s shares of common stock are expected to begin trading on Nasdaq on August 26, 2025, under the ticker symbol "CURX."
The company has granted the underwriters an option, exercisable within 45 days from the close of the offering, to purchase up to 562,500 additional shares of common stock at the public offering price, less underwriting discounts and expenses.
The offering is expected to close on August 27, 2025.
The company intends to use the proceeds from the offering for: (i) the development of our lead product candidate, Phyto-N, for the treatment of ulcerative colitis; (ii) to conduct FDA-required good laboratory practice toxicology and pharmacokinetic studies for Phyto-N in ulcerative colitis, (iii) to prepare and submit an Investigational New Drug (IND) application, and (iv) for working capital and other general corporate purposes.
Source: Press Release

More on Curanex Pharmaceuticals Inc